| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
ARTICLE |
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
Affiliations of authors: Lab of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain (SI, MRC, NZ, ALD, HV, ES, MB); General Flow Cytometry Service, Center for Cancer Investigation, University of Salamanca, Salamanca, Spain (LS, ARC, AO); Department of Immunology (FP), Department of Hematology (RGM, CP, JPC, ER), Cell Therapy Area (IM), University Clinic, University of Navarra, Pamplona, Spain
Correspondence to: Maurizio Bendandi, MD, PhD, Lab of Immunotherapy, Oncology Division, Rm. 1.06, Center for Applied Medical Research (CIMA), Avda. Pio XII, 55, 31008 Pamplona (Navarra), Spain (e-mail: mbendandi{at}unav.es).
Background: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. A patient's second complete response is typically shorter than that patient's first complete response. Idiotype vaccines can elicit specific immune responses and molecular remissions in patients with follicular lymphoma. However, a clinical benefit has never been formally proven. Methods: Thirty-three consecutive follicular lymphoma patients in first relapse received six monthly cycles of CHOP-like chemotherapy. Patients who achieved a second complete response were vaccinated periodically for more than 2 years with autologous lymphoma-derived idiotype protein vaccine. Specific humoral and cellular responses were assessed, and patients were followed for disease recurrence. Statistical tests were two-sided. Results: Idiotype vaccine could be produced for 25 patients who had a second complete response. In 20 patients (80%), a humoral (13/20) and/or a cellular (18/20) idiotype-specific response was detected. The median duration of the second complete response has not been reached, but it exceeds 33 months (range = 20+ to 51+ months). None of the 20 responders relapsed while undergoing active vaccination. All responders with enough follow-up for the comparison to be made experienced a second complete response that was statistically significantly (P<.0001) longer than both their first complete response (18 of 18 patients) and than the median duration of a CHOP-induced second complete response, i.e., 13 months (20 of 20 patients). The five nonresponders all had a second complete response that was shorter (median = 10 months; range = 8–13 months) than their first complete response (median = 17 months; range = 10–39 months). Conclusions: Idiotypic vaccination induced a specific immune response in the majority of patients with follicular lymphoma. Specific immune response was associated with a dramatic and highly statistically significant increase in disease-free survival. This is the first formal demonstration of clinical benefit associated with the use of a human cancer vaccine.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Idiotype Vaccination in Follicular Lymphoma: Knocking on the Doorway to Cure
- Dan L. Longo
J Natl Cancer Inst 2006 98: 1263-1265.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini, A. Molla, C. Vegetti, S. Albani, A. Anichini, and A. M. Gianni The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells Haematologica, October 1, 2008; 93(10): 1523 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas J. Immunol., September 15, 2008; 181(6): 4131 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study PNAS, July 22, 2008; 105(29): 10131 - 10136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC) Ann. Onc., June 1, 2008; 19(6): 1172 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Houot and R. Levy Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 3 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Neelapu and L. W. Kwak Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies Hematology, January 1, 2007; 2007(1): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Longo Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J Natl Cancer Inst, September 20, 2006; 98(18): 1263 - 1265. [Full Text] [PDF]
|
|